Scorpius Holdings Enters Material Agreement, Reports Equity Sales

Ticker: SCPX · Form: 8-K · Filed: Sep 24, 2025 · CIK: 1476963

Scorpius Holdings, Inc. 8-K Filing Summary
FieldDetail
CompanyScorpius Holdings, Inc. (SCPX)
Form Type8-K
Filed DateSep 24, 2025
Risk Levelmedium
Pages3
Reading Time3 min
Key Dollar Amounts$128,000, $150,000
Sentimentneutral

Sentiment: neutral

Topics: material-agreement, financial-obligation, equity-sale

Related Tickers: SCPX

TL;DR

SCPX inked a deal, owes money, and sold stock. Big moves happening.

AI Summary

On September 22, 2025, Scorpius Holdings, Inc. entered into a material definitive agreement and incurred a direct financial obligation. The company also reported unregistered sales of equity securities. This filing follows a name change from NightHawk Biosciences, Inc. on May 2, 2022.

Why It Matters

This filing indicates new financial commitments and equity transactions for Scorpius Holdings, which could impact its financial structure and shareholder base.

Risk Assessment

Risk Level: medium — The filing details material definitive agreements and unregistered equity sales, which can introduce financial obligations and dilution risks.

Key Players & Entities

  • Scorpius Holdings, Inc. (company) — Registrant
  • NightHawk Biosciences, Inc. (company) — Former company name
  • September 22, 2025 (date) — Date of earliest event reported
  • May 2, 2022 (date) — Date of former company name change

FAQ

What is the nature of the material definitive agreement entered into by Scorpius Holdings, Inc. on September 22, 2025?

The filing indicates the entry into a material definitive agreement, but the specific details of the agreement are not provided in the provided text.

What is the direct financial obligation incurred by Scorpius Holdings, Inc.?

The filing states that Scorpius Holdings, Inc. incurred a direct financial obligation, but the specific amount and terms are not detailed in the provided text.

What were the circumstances of the unregistered sales of equity securities?

The filing reports unregistered sales of equity securities, but the specifics regarding the number of shares, price, and purchasers are not included in the provided text.

When did Scorpius Holdings, Inc. change its name from NightHawk Biosciences, Inc.?

Scorpius Holdings, Inc. changed its name from NightHawk Biosciences, Inc. on May 2, 2022.

What is the SIC code for Scorpius Holdings, Inc.?

The Standard Industrial Classification (SIC) code for Scorpius Holdings, Inc. is 2834, which corresponds to Pharmaceutical Preparations.

Filing Stats: 793 words · 3 min read · ~3 pages · Grade level 11.4 · Accepted 2025-09-24 16:30:25

Key Financial Figures

  • $128,000 — Hundred Twenty-Eight Thousand Dollars ($128,000) to an institutional investor (the "Hol
  • $150,000 — fails to pay indebtedness in excess of $150,000 due to any third party, subject to cert

Filing Documents

01. Entry Into a Material Definitive Agreement

Item 1.01. Entry Into a Material Definitive Agreement. On September 22, 2025, Scorpius Holdings, Inc., a Delaware corporation (the "Company"), issued a non-convertible promissory note (the "Note") in the principal amount of One Hundred Twenty-Eight Thousand Dollars ($128,000) to an institutional investor (the "Holder"). The Note accrues interest at the rate of 5.0% per annum and matures on the earlier of: (i) October 31, 2025; (ii) the consummation of a Corporate Event (as such term is defined in the Note); or (iii) when, upon or after the occurrence of an event of default under the Note. All payments by the Company upon maturity, redemption or prepayment of the Note shall include, together with all other amounts of principal and/or interest, a premium payment equal to 5% of the principal amount of the Note. The Note contains customary events of default, including if the Company or any of its subsidiaries, individually or in the aggregate, fails to pay indebtedness in excess of $150,000 due to any third party, subject to certain exceptions, or if an event of default occurs under any other outstanding promissory note of the Company. If at any time the Note is outstanding the Company consummates a subsequent Financing (as such term is defined in the Note), the Holder shall have the right, it its sole discretion, to require that the Company redeem the entire outstanding balance of the Note, together with all accrued interest thereon, using up to 100% of the gross proceeds of such Financing. The Company sold the Note in reliance upon an exemption from registration contained in Section 4(a)(2) of the Securities Act of 1933, as amended and/or Regulation D promulgated thereunder. The foregoing description of the Note is qualified in its entirety by reference to the full text of the Note, a copy of which is attached hereto as Exhibit 4.1, and which is incorporated herein in its entirety by reference.

03. Creation of a Direct Financial Obligation

Item 2.03. Creation of a Direct Financial Obligation or an Obligation Under an Off-balance Sheet Arrangement of a Registrant. The information set forth under Item 1.01 above of this Current Report on Form 8-K is incorporated by reference in this Item 2.03.

02. Unregistered

Item 3.02. Unregistered Sales of Equity Securities. The information set forth under Item 1.01 above of this Current Report on Form 8-K is incorporated by reference in this Item 3.02. The Note was issued pursuant to an exemption from the registration requirements under Section 4(a)(2) of the Securities Act and/or Rule 506 of Regulation D promulgated thereunder. The Note may not be offered or sold in the United States in the absence of an effective registration statement or exemption from the registration requirements.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit Number Exhibit Description 4.1 Form of Promissory Note 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: September 24, 2025 SCORPIUS HOLDINGS, INC. By: /s/ Jeffrey Wolf Name: Jeffrey Wolf Title: Chairman, President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.